$937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment$
QR Code

937P Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment

Saved in:

Bibliographic Details
Published in:	Annals of oncology Vol. 34; pp. S589 - S590
Main Authors:	Jové, M., Braña, I., Oliva Bernal, M., Hernando Calvo, A., Erasun Lecuona, C., Assaf Pastrana, J.D., Mato-Berciano, A., Maliandi, M.V., Torres-Manjon, S., Moreno, R., Le, C., Nuciforo, P.G., Alemany, R., Capella, G., Blasco, C., Cascallo Piqueras, M., Mesia Nin, R.
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01-10-2023
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	0923-7534 1569-8041
DOI:	10.1016/j.annonc.2023.09.2081